Genetic and immunologic susceptibility to statin-related myopathy

Jaideep Patel, H. Robert Superko, Seth Martin, Roger S Blumenthal, Lisa Christopher-Stine

Research output: Contribution to journalArticle

Abstract

Statin-related myopathy (SRM) undermines drug adherence that is critical for achieving the benefits of lipid-lowering therapy. While the exact mechanism of SRM remains largely unknown, recent evidence supports specific genetic and immunologic influence on the development of intolerance. Genes of interest include those involved in the pharmacokinetics of statin response (i.e. drug metabolism, uptake transporters, and efflux transporters), pharmacodynamics (i.e. drug toxicity and immune-mediated myopathy), and gene expression. We examine the influence of genetic and immunologic variation on the pharmacokinetics, pharmacodynamics, and gene expression of SRM.

Original languageEnglish (US)
Pages (from-to)260-271
Number of pages12
JournalAtherosclerosis
Volume240
Issue number1
DOIs
StatePublished - May 1 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscular Diseases
Genetic Predisposition to Disease
Pharmacokinetics
Gene Expression
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Lipids
Genes
Therapeutics

Keywords

  • Anti-HMGCR
  • Pharmacogenomics
  • SLCO1B1
  • Statin-related myopathy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Genetic and immunologic susceptibility to statin-related myopathy. / Patel, Jaideep; Superko, H. Robert; Martin, Seth; Blumenthal, Roger S; Christopher-Stine, Lisa.

In: Atherosclerosis, Vol. 240, No. 1, 01.05.2015, p. 260-271.

Research output: Contribution to journalArticle

@article{0149e4ad47894b79a4826935ce1aa79b,
title = "Genetic and immunologic susceptibility to statin-related myopathy",
abstract = "Statin-related myopathy (SRM) undermines drug adherence that is critical for achieving the benefits of lipid-lowering therapy. While the exact mechanism of SRM remains largely unknown, recent evidence supports specific genetic and immunologic influence on the development of intolerance. Genes of interest include those involved in the pharmacokinetics of statin response (i.e. drug metabolism, uptake transporters, and efflux transporters), pharmacodynamics (i.e. drug toxicity and immune-mediated myopathy), and gene expression. We examine the influence of genetic and immunologic variation on the pharmacokinetics, pharmacodynamics, and gene expression of SRM.",
keywords = "Anti-HMGCR, Pharmacogenomics, SLCO1B1, Statin-related myopathy",
author = "Jaideep Patel and Superko, {H. Robert} and Seth Martin and Blumenthal, {Roger S} and Lisa Christopher-Stine",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.atherosclerosis.2015.03.025",
language = "English (US)",
volume = "240",
pages = "260--271",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Genetic and immunologic susceptibility to statin-related myopathy

AU - Patel, Jaideep

AU - Superko, H. Robert

AU - Martin, Seth

AU - Blumenthal, Roger S

AU - Christopher-Stine, Lisa

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Statin-related myopathy (SRM) undermines drug adherence that is critical for achieving the benefits of lipid-lowering therapy. While the exact mechanism of SRM remains largely unknown, recent evidence supports specific genetic and immunologic influence on the development of intolerance. Genes of interest include those involved in the pharmacokinetics of statin response (i.e. drug metabolism, uptake transporters, and efflux transporters), pharmacodynamics (i.e. drug toxicity and immune-mediated myopathy), and gene expression. We examine the influence of genetic and immunologic variation on the pharmacokinetics, pharmacodynamics, and gene expression of SRM.

AB - Statin-related myopathy (SRM) undermines drug adherence that is critical for achieving the benefits of lipid-lowering therapy. While the exact mechanism of SRM remains largely unknown, recent evidence supports specific genetic and immunologic influence on the development of intolerance. Genes of interest include those involved in the pharmacokinetics of statin response (i.e. drug metabolism, uptake transporters, and efflux transporters), pharmacodynamics (i.e. drug toxicity and immune-mediated myopathy), and gene expression. We examine the influence of genetic and immunologic variation on the pharmacokinetics, pharmacodynamics, and gene expression of SRM.

KW - Anti-HMGCR

KW - Pharmacogenomics

KW - SLCO1B1

KW - Statin-related myopathy

UR - http://www.scopus.com/inward/record.url?scp=84925396361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925396361&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2015.03.025

DO - 10.1016/j.atherosclerosis.2015.03.025

M3 - Article

VL - 240

SP - 260

EP - 271

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -